

ADVANCES IN TARGETED THERAPY FOR BREAST CANCER: CURRENT STATUS AND FUTURE DIRECTION

Kalavala Lakshmi Gayatri¹, Sirigubattula Naga Jyothi², Gottumukkala Tejaswi³, Pothala Raji Chandrika⁴, Gubbala Jeevabhishek⁵, Repuri Ramya Padma Sri⁶, Bheemavarapu Jayanth⁷, Kiran Manda^{8*}

^{1,3} Department of Pharmaceutical Quality Assurance, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari District, Andhra Pradesh – 534202

² Pharm.D, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari District, Andhra Pradesh – 534202

^{4,5,6} Department of Pharmaceutical Quality Assurance, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari District, Andhra Pradesh – 534202

⁷ Department of Pharmaceutical Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari District, Andhra Pradesh – 534202

^{8*} Associate Professor, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari District, Andhra Pradesh - 534202, 9492879141, kiranmanda15@gmail.com

ABSTRACT:

Breast cancer remains one of the leading causes of cancer related morbidity and mortality in women worldwide. Recent advances in molecular biology have led to the development of targeted therapies that have improved outcomes in patients with breast cancer. This review provides a comprehensive overview of the molecular subtypes of breast cancer and the current status of targeted therapies, including HER2 – targeted treatments, hormone receptor antagonists, CDK4/6 inhibitors, and PI3K/AKT/m TOR pathway inhibitors. The article also discusses emerging therapeutic approaches such as antibody – drug conjugates, immunotherapy, and medicine. Furthermore, it outlines challenges such as drug resistance, accessibility issues, and the need for predictive biomarkers. Finally, this review examines future directions in targeted therapies for breast cancer, including the role of personalized medicine, combination therapies, and innovative drug delivery systems.

KEYWORDS: Breast cancer, Targeted Therapy, HER2, Hormone Receptor, CDK4/6, PI3K/AKT/mTOR, Immunotherapy, Personalized Medicine.

INTRODUCTION

Breast cancer is one of the most common and heterogeneous cancers, affecting millions of women across the globe [1]. The prognosis and therapeutic approach for patients with breast cancer vary significantly depending on the molecular and histopathological characteristics of the tumor. [2] Traditional treatments, including surgery, chemotherapy, and radiotherapy, have improved survival rates; however, these therapies are often associated with severe side effects and lack specificity, leading to incomplete responses and relapse in some patients. [3]

The advent of targeted therapies has significantly transformed breast cancer management by offering a more personalized approach that focuses on specific molecular targets involved in tumor growth and progression [4]. Targeted therapies have not only improved the outcomes for certain sub-types of breast cancer but also provided patients with more effective and less toxic treatment options. [5]

This review discusses the molecular basis of breast cancer, current targeted therapies, emerging treatment modalities, and the future directions in the management of this disease. This review aims to provide a comprehensive overview for both researchers and clinicians interested in the evolving landscape of targeted breast cancer therapies. [6] [7].

2. Molecular Classification of Breast Cancer

Breast cancer is a genetically diverse disease with varying responses to treatment based on molecular subtype. The introduction of molecular profiling has enabled the classification of breast cancer into different subtypes, each characterized by distinct molecular markers that influence prognosis and treatment response. These sub-types include [8].




Fig: 1 This image explains the five main intrinsic or molecular subtypes of breast cancer ,along with their characteristics, prevalence, prognosis, and targeted therapies. [9]

2.1 Luminal A Breast Cancer

Luminal A tumors are estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and human epidermal growth factor receptor 2-negative (HER2-). [10] [11] These tumors are generally associated with a good prognosis and exhibit low levels of Ki-67 (a marker of proliferation) [12]. [13]. It is the most common subtype of breast cancer (approximately 40-50% of cases). It is often detected at earlier stages and has a better prognosis than other subtypes. Luminal A tumors are typically treated with endocrine therapy, such as tamoxifen (for premenopausal women) [14] and aromatase inhibitors (AI) (for postmenopausal women). [14]. [15]

2.12 Luminal A Breast cancer may manifest through a variety of signs . These potential symptoms include:

Breast abnormalities present with some physical changes. One of the most common sign is a Palpable mass or lump detected in the breast tissue. Some of the individuals experience, Discomfort or tenderness in breast region. Fluid or abnormal drainage emanating from nipple should also be considered as warning sign. In addition, changes to the skins texture such as thickening, hardening, or dimpled appearance also observed.

2.13 Causes of Luminal A Breast Cancer

Regular intake of alcohol increases the risk of breast cancer by raising the levels of estrogen and other hormones promote the growth of the breast tissues, harmful compounds like free radicals are produced during alcohol metabolism, which can damage DNA and increase the risk of cancer development. Being older than 50 is the strongest risk factor due to breast cells undergo repeated cycles of division, increases the chance the genetic mutations. Most of the breast cancer cases are diagnosed in women over the age of 50. Late onset of menopause, women who experience menopause after the age of 55 have higher risk due to the longer exposure of estrogen and progesterone. Prolonged exposure of these hormones stimulates breast cell growth, increases the chances of DNA damage and development of cancerous cells. Long term use of hormone therapy medications stimulates estrogen receptor-positive breast cells leads to cell proliferation and increases the chances of development of breast cancer. Previous radiation therapy directed at the chest area. Ionizing radiation can damage the DNA of healthy breast cells, leading to permanent genetic mutations, they may develop into hormone receptor-positive breast cancers.

2.14 Treatment

Chemotherapy is often required unless the tumor is large, lymph nodes are involved, or the cancer shows higher-risk features. [14] [11].

Treatment for Luminal A breast cancer typically involves a combination of local and systemic therapies. Local treatment approaches include radiation and surgery. Systemic treatment may consist of hormone therapy or chemotherapy. Due to the nature of Luminal A breast cancer being hormone receptor-positive, its growth is dependent on estrogen. Consequently, this type of cancer responds effectively to hormone therapy, which is a targeted therapeutic strategy. It is important to distinguish this from hormone replacement therapy, which is sometimes utilized to alleviate menopausal symptoms.

In women who have not yet reached menopause, the primary source of estrogen is the ovaries. Therefore, a critical approach to lowering estrogen production involves ovarian suppression. Targeted therapy; her2 drug (like trastuzumab) are not used, because luminal A is HER2-negative [16]

2.2 Luminal B Breast Cancer

They can be classified based on gene expression profiles, hormone receptor status, and tumor characteristics [17] [10]. Luminal B tumors are also ER+/PR+ but differ from Luminal A in that they may be HER2-positive or have higher

Ki-67 expression [10] [11]. [18] Luminal B tumors tend to be more aggressive than Luminal A tumors [11] [10] and may require additional treatments, such as chemotherapy [11] and HER2-targeted therapies [19]

2.21 Causes of Luminal B Breast Cancer :

Being over age of 50. The risk of developing Luminal B breast cancer increases with advancing age. As people grow older, genetic alterations occur due to repeated cell division and decline in the efficiency of DNA repair mechanisms, this increases the likelihood of cancer development. Inheriting specific genetic mutations occurs in specific genes such as BRCA2, PALB2 and CHEK2 can increase the risk of developing Luminal B breast cancer. These genes normally regulate cell growth, when mutations occur abnormal cells are more likely to survive, accumulate additional mutations, and eventually may develop into cancer. Regular alcohol intake increases circulating estrogen levels and promotes oxidative stress. Elevated estrogen levels stimulate the growth and proliferation of the hormone receptor-positive breast cells, while reactive oxygen species produced during the alcohol metabolism can damage the cellular DNA. Together, these effects may contribute to the development of this aggressive hormone receptor-positive subtype. Women having highly dense breast tissue have a greater risk of developing Luminal B breast cancer. Dense breast contains a higher proportion of glandular and fibrous tissue and less fatty tissue, providing more cells that can undergo abnormal changes, and also associated with enhanced hormonal activity and growth factor signaling, which may promote tumor development.

2.22 Symptoms of Luminal B Breast Cancer

A common symptom of Luminal B breast cancer is persistent discomfort or pain in one or both breasts. Changes in the appearance of one or both nipples such as inversion, retraction, flattening, or deviation from its normal position, may also occur due to underlying tumor. Skin over the affected breast may undergo changes such as redness, a dimpled texture, swelling, or hardening. In addition, nipple discharge that is not breast milk, especially if it is bloody or occurs spontaneously, should be considered as warning sign of breast cancer and requires prompt medical evaluation.

2.23 Treatment

Treatment approaches like Endocrine therapy -tamoxifen, aromatase inhibitors, or ovarian suppression. Chemotherapy (often recommended due to higher aggressiveness.) Targeted therapy and CDK4/6 inhibitors are used in advanced/metastatic cases. [20] [21]

2.3 HER2-Enriched Breast Cancer

It is defined by gene expression profiling [22]. HER2-positive breast cancers overexpress the HER2 receptor [22]. These tumors are aggressive and account for approximately 15–20% of all breast cancer cases [23] [24] [22]. There is higher risk of recurrence and metastasis [25] [26].

2.31 Symptoms of HER2-Enriched Breast Cancer:

HER2-enriched breast cancer may cause noticeable changes in the size, shape, or contour of the affected breast. As the tumor grows rapidly, the breast may appear swollen, enlarged, or asymmetrical compared with the opposite breast. These changes often become more apparent as the disease progresses. Breast lump is one of the most common symptoms of HER2-enriched breast cancer. The lump is typically firm, irregular in shape, and may initially be as small as a pea. Due to the aggressive nature of this subtype, the mass may increase in size more rapidly than other forms of breast cancer. A thickened area or persistent lump in the breast or armpit that does not disappear over time or after the menstrual cycle should be evaluated promptly. These changes may result from tumor growth or the spread of cancer to nearby lymph nodes and are often associated with disease progression. The skin over the affected breast may become red, inflamed, scaly, puckered, or dimpled because of tumor involvement of the skin and lymphatic vessels. Changes in the nipple, such as inversion, flattening, or displacement from its normal position, may also occur as the tumor enlarges. Some patients may develop a firm, hardened area beneath the skin that feels similar to a small marble. This occurs when the tumor invades the surrounding tissues, leading to fibrosis and hardening of the breast tissue. The affected area is often less movable and may become more noticeable as the disease advances.

2.32 Causes of HER-2 Enriched Breast cancer :

Possessing an inherited gene variant, such as BRCA1 OR BRCA2 have a higher risk of developing breast cancer, these genes normally function as tumor suppressors and also regulate cell growth. Mutations impair these protective mechanisms may lead to development of aggressive breast cancer. Women with a previous history of breast cancer have a greater risk of developing a breast cancer. Residual genetic abnormalities, underlying susceptibility, and previous exposure to risk factors may contribute to the development of HER2-enriched tumors. Precancerous breast lesions, such as atypical ductal hyperplasia (ADH), are associated with an increased risk of breast cancer. Women who begin menstruation at an early age, typically before 12 years, are exposed to estrogen for a longer period during their lifetime. Prolonged hormonal exposure increases the number of breast cell divisions, raising the chance of DNA mutations and increasing the risk of developing breast cancer, including the HER2-enriched subtype. Women who experience menopause after the age of 55 have prolonged exposure to estrogen and progesterone. This extended hormonal stimulation promotes repeated growth and division of breast cells, increasing the likelihood of genetic mutations. Over time, these accumulated genetic changes may contribute to the development of HER2-enriched breast cancer.

Treatment:

HER2-targeted therapies, such as trastuzumab (Herceptin) monoclonal antibody targeting HER2 [25] and pertuzumab have significantly improved survival outcomes in this subgroup [25] [27]. T-DM1 antibody conjugate [27]. Trastuzumab deruxtecan [28] and Tyrosine kinase inhibitors [29]. Chemotherapy is administered in combination with HER2-targeted therapy [27] [25]. Endocrine therapy is not useful (since HR is usually negative) [30] [31]

2.4 Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer (TNBC) refers to tumors that are negative for ER, PR, and HER2. These tumors are typically more aggressive, with a higher likelihood of metastasis and poor prognosis [32]. TNBC typically exhibits faster growth compared to many other types of breast cancer and has a higher chance of returning after initial treatment.

2.41 Symptoms of Triple-Negative Breast Cancer :

One of the most common symptoms of the triple-negative breast cancer is the presence of a lump or dense area discovered in the breast or armpit. The lump is usually painless, has irregular borders, and may increase in size rapidly due to aggressive nature of the disease. Patient may also notice changes in the overall size or contour of the breast. The skin over the affected may develop dimpling or a pitted appearance because the tumor pulls on the surrounding tissues or blocks the lymphatic vessels. In some cases spontaneous nipple discharged or nipple retraction may occur due to involvement of breast ducts. Additionally, changes in the skin around the nipple, such as flakiness, redness, or thickening may also be observed.

2.42 Causes of TNBC:

Inherited mutations in specific genes like BRCA1 and occasionally BRCA2, results in a higher susceptibility. These genes are normally function as tumor suppressors. When these genes are mutated, leading to uncontrolled cell growth increasing likelihood of developing TNBC. TNBC is more frequently diagnosed in younger patients, commonly those under the age 50, making it more prevalent in this group compared to other forms of breast cancer. Studies have shown that triple-negative breast cancer occurs more commonly among Black and Hispanic women than in women of other racial or ethnic groups. The increased risk is believed to result from a combination of inherited genetic factors, biological differences, environmental influences, and socioeconomic factors that affect access to healthcare and early detection. Individuals with a family history of breast or ovarian cancer have a higher risk of developing triple-negative breast cancer. A strong family history may indicate the presence of inherited genetic mutations, particularly in the BRCA1 gene, which substantially increases susceptibility to this subtype.

2.43 Treatment:

Treatment options for TNBC are limited, making it a focus of intense research, particularly for targeted therapies and immunotherapies [33]. Advanced/targeted options ; Immunotherapy like (pembrolizumab, atezolizumab) [34] PARP inhibitors (for patients with BRCA1/2 mutations) [35] [36]. Antibody-drug conjugates (Sacituzumab, govitecan is approved for metastatic TNBC after prior treatment) [37] [38]




Fig 2: This image explains the molecular subtypes of Triple-Negative Breast Cancer(TNBC) and the different targeted therapy approaches being developed for them. [39]

3. Current Targeted Therapies for Breast Cancer

Over the past two decades, several targeted therapies have been developed and implemented for breast cancer treatment [40]. These therapies focus on specific molecular targets that drive tumor growth, offering a more effective and less toxic approach than traditional chemotherapy [41] [42]. These therapies exploit well-characterized molecular targets—

such as HER2, PI3K, CDK4/6, and PARP—to selectively inhibit tumor growth, improve efficacy, and reduce toxicity compared to conventional cytotoxic treatments. [43] [44].

The advancement of breast cancer is significantly influenced by estrogen and its corresponding receptors, consequently, inhibiting the estrogen signaling pathway has been a long standing treatment strategy for women with estrogen-positive disease. To suppress tumor growth in estrogen-dependent cancers and reduce the recurrence rate by an estimated 40-50%, agents such as Selective Estrogen Receptors Modulators (SERMs) have been employed, with tamoxifen being the first drug authorized by the FDA for estrogen-positive metastatic breast cancer.

Aromatase inhibitors, including anastrozole, letrozole, and exemestane, offer an alternative treatment for estrogen-dependent breast cancers. These drugs work by inhibiting the aromatase enzyme, thereby blocking the conversion of androgens into estrogen and lowering estrogen levels within the tumor.

For breast cancers that are not hormone-dependent, different therapies are necessary. The HER2 protein is widely recognized as the most frequently overexpressed receptor signature in this cancer type and is an important biomarker guiding treatment. Trastuzumab, a recombinant antibody targeting HER2, was the first medication approved by the FDA in 1998 for treating HER2-positive breast cancers.

In the treatment of HER2-positive breast cancer, the antibody-drug conjugate TDM1 offers a targeted approach. This therapy utilizes trastuzumab to deliver DM1—a potent microtubule inhibitor—directly into malignant cells to arrest their growth. For TNBC which lacks hormone receptors and HER2 expression, PARP1 inhibitors and potential options. Notably, phase 2 data suggest that pairing cetuximab with cisplatin may be effective for certain TNBC subtypes sensitive to EGFR inhibition.

While standard chemotherapy involving anthracyclines and taxanes remains the primary treatment for TNBC, researchers are actively seeking more specific molecular targets. For instance, patients resistant to traditional taxane or anthracycline regimens may benefit from combining ixabepilone with capecitabine, a strategy currently under phase 3 investigation. Furthermore, bevacizumab has demonstrated efficacy in treating advanced metastatic cases when combined with taxanes by targeting the vascular endothelial growth factor. Other therapeutic avenues include targeting tyrosine kinases and downstream signaling pathways, such as PI3K/AKT/mTOR and RAS/MEK/ERK.

3.1 HER2-Targeted Therapies

HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer [45]. The discovery and use of monoclonal antibody trastuzumab around 25 years ago is described as having “revolutionized treatment and drug development for HER2⁺ breast cancer” [46]. Reviews note that HER2-directed therapies have “dramatically influenced the outcome of patients with HER2-positive breast... cancers” [45]. The HER2 receptor, when overexpressed, promotes tumor growth and metastasis [47]. HER2 is a tyrosine kinase transmembrane glycoprotein in the EGFR family; its aberrant overexpression is associated with aggressive tumor behaviour, including proliferation and metastasis [45]. Amplification or overexpression occurs in about 20–30% of breast cancers and correlates with increased disease recurrence and poorer prognosis, including metastasis [48] [49]. Targeting HER2 with monoclonal antibodies and tyrosine kinase inhibitors has proven to be highly effective [50]. HER2-targeted therapies—including monoclonal antibodies and TKIs—have significantly improved survival in HER2-positive breast cancer [50]. Monoclonal antibodies like trastuzumab (FDA-approved 1998) and pertuzumab (FDA-approved 2012) have become standard of care and extended patient outcomes [51]. TKIs such as lapatinib and neratinib inhibit HER2 kinase activity and are associated with improved survival [48] [49]. It is the human epidermal growth factor receptor 2 (HER2/ERBB2) protein or have HER2 gene amplification. HER2 (ERBB2) is a member of the human epidermal growth factor receptor family, functioning as a receptor tyrosine kinase [45]. In breast cancer, HER2 gene amplification is the principal cause of its protein overexpression, occurring in approximately 15–30% of cases [47] [45].




Fig :3 This image explains how Herceptin (trastuzumab) works in treating HER2-positive breast cancer [52]

Trastuzumab: Trastuzumab (Herceptin) was the first monoclonal antibody approved for the treatment of HER2-positive breast cancer [53]. By binding to the extracellular domain IV of the HER2 receptor, trastuzumab inhibits downstream signaling pathways MAPK, PI3K/AKT) and enhances immune-mediated destruction of cancer cells [54]. It promotes antibody-dependent cellular cytotoxicity [54]. It prevents HER2 receptor shedding, which maintains immune recognition [55]. It is administered through intravenous infusion (loading dose, then every 1-3 weeks) and also through subcutaneously with fixed dose formulation. [56]

Toxicity ; cardiotoxicity (reversible LVEF decrease, heart failure risk, especially with anthracyclines), [57] Infusion-related reactions (fever, chills, rash, anaphylaxis rare), Mild hematologic toxicity when combined with chemo [56].

Impact; Approved in 1998 for HER2+metastatic breast cancer [58] . First HER2-targeted therapy for revolutionized outcomes. Turned HER2+breast cancer into a treatable subtype with much better survival [59]

Pertuzumab : Pertuzumab is a second monoclonal antibody that binds to a different epitope of the HER2 receptor, preventing dimerization with other HER receptors and further inhibiting tumor growth [60] .Also mediates antibody dependent cellular cytotoxicity [61].It binds to extracellular domain II of HER2 receptor [62].It is administered through IV infusion and continued with trastuzumab until progression or unacceptable toxicity. [63]

Toxicity, such as cardiotoxicity, diarrhea, rash, infusion related reactions, neutropenia (mainly due to chemotherapy combination, not pertuzumab itself). [64]

Impact; First approved in 2012 (metastatic breast cancer, CLEOPATRA trial) [64] . The trial demonstrated significant improvements in progression-free survival (e.g., from ~12.4 to ~18.5 months, HR ≈ 0.62) and a substantial increase in median overall survival, with an approximate 15.7-month advantage (e.g., 56.5 vs. 40.8 months) [65].When combined with trastuzumab, there is a significant improvement in progression-free survival and overall survival, establishing the standard dual HER2 blockade approach in breast cancer . [63]

T-DM1 (Ado-trastuzumab emtansine): T-DM1 is an antibody-drug conjugate (ADC) that combines trastuzumab with the cytotoxic drug DM1 [66] [67]. This therapy allows the targeted delivery of chemotherapy directly to HER2-positive cancer cells, thereby minimizing systemic toxicity [68] .A stable linker attaches trastuzumab to DM1. [69] [70]. DM1 part; internalized into HER2+tumor cells .It act by inhibiting microtubule polymerization, which may lead to apoptosis. [67] [71]. Toxicity; Hepatotoxicity, thrombocytopenia, peripheral neuropathy, cardiotoxicity ,infusion reactions, fatigue, nausea, constipation. [72]. **Impact**; FDA approved in the 2013 for metastatic breast cancer) . [73]

Tyrosine Kinase Inhibitors (TKIs): These are small molecules oral drugs that block the intracellular kinase activity of HER receptors, preventing phosphorylation and downstream signaling(MAPK,PI3K/AKT) [74] [75].Drugs such as lapatinib, pyrotinib, tucatinib and neratinib specifically inhibit HER2 signaling through the tyrosine kinase domain, providing another treatment option for patients who may develop resistance to monoclonal antibodies. [76]

Drug	HER Targets	Used for	Notable Side effects
Lapatinib	HER2+EGFR	MetastaticHER2+(with capecitabine or letrozole)	Diarrhea,rash,hepatotoxicity
Pyrotinib	Pan-HER	Investigational	Rash, diarrhea
Tucatinib	Highlyselective HER2	Metastatic HER2+(esp.brainmets)	Diarrhea,hepatotoxicity
Neratinib	HER1,HER2,HER4	Extendedadjuvant after trastuzumab	Severe diarrhea

Hormone Receptor-Targeted Therapy:

Hormone therapy is the cornerstone of treatment for estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast cancers. Endocrine (hormone) therapy is an essential component for treating breast cancers that express ER and/or PR, across both early and advanced stages [77]. Specifically, ER-positive breast cancers are highly responsive to treatments that interfere with estrogen signaling, making hormone therapy foundational [78].These cancers are driven by the hormonal signaling pathways, and targeting these pathways can significantly reduce tumor growth. ER and PR are hormone receptors that, when activated by estrogen and progesterone, stimulate gene transcription leading to tumor cell proliferation [79] . About 70–80% of breast cancers express ER and/or PR, reinforcing that these tumors are growth-driven by hormone signaling and are thus highly sensitive to endocrine intervention [80]

Tamoxifen : A selective estrogen receptor modulator (SERM), it exhibits tissue-dependent agonist and antagonist effects on estrogen receptors [81]. Tamoxifen competitively binds to estrogen receptors in breast tissue, blocking estrogen from binding; this inhibits estrogen-driven transcription, slows cell proliferation, blocks G₁ phase of the cell cycle, and can cause tumor regression [82]. Tamoxifen is used in both early-stage and metastatic ER+ breast cancers [81] [82] .It is mainly used as an adjuvant therapy for premenopausal and postmenopausal women . [83]. Toxicities include hot flashes, thromboembolism [84] and an increased risk of endometrial carcinoma due to agonist effect. [83] [85]

Aromatase Inhibitors (AIs): Drugs like letrozole, anastrozole, and exemestane inhibit the enzyme aromatase, which is responsible for converting androgens into estrogens [86]. AIs are particularly effective in postmenopausal women, who have lower ovarian estrogen levels [87]. It is used for adjuvant , neoadjuvant therapies [88]. Toxicity; Arthralgia,myalgia,osteoporosis [89], hot flashes. [90]. Arthralgia myalgia :Musculoskeletal symptoms including arthralgia and myalgia occur frequent third-generation aromatase inhibitors have proven to be more effective than tamoxifen. However, AIs further reduce plasma estrogens in [postmenopausal women], exacerbating musculoskeletal symptoms.[91]

“Approximately 25% of postmenopausal women with early breast cancer report experiencing symptoms of arthralgia with AI therapy, ... in the MA.17 trial revealed marked increases in arthralgia (25% vs. 21%) and myalgia (15% vs. 12%) in patients on letrozole as compared with those on placebo. [92]”

Fulvestrant: A selective estrogen receptor degrader (SERD), fulvestrant works by promoting the degradation of the estrogen receptor, Fulvestrant binds to the estrogen receptor (ER), induces a conformational change that inhibits

receptor dimerization and nuclear localization, and flags the receptor for degradation through the ubiquitin-proteasome system, resulting in diminished estrogen signaling [93] [94]. Fulvestrant is approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, particularly after progression on prior endocrine therapy such as tamoxifen or aromatase inhibitors [95]. Its combination with CDK4/6 inhibitors (e.g., palbociclib, ribociclib, or abemaciclib) has been shown in randomized trials (e.g., PALOMA-3) to significantly improve progression-free survival compared to fulvestrant alone. [96] Toxicity; Injection site reactions (IM only) [97] [96]

Ovarian Function Suppression (OFS): Ovarian suppression uses drug therapy to prevent the ovaries from producing estrogen, effectively inducing a temporary menopausal state in premenopausal women with hormone receptor-positive breast cancer [98]. Common drugs include GnRH agonists such as leuprolide and goserelin. GnRH (or LHRH) agonists work by downregulating pituitary receptors, decreasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, which in turn reduces ovarian estrogen production [99]. Surgical removal of the ovaries (oophorectomy) leads to an immediate and permanent cessation of estrogen and progesterone production, resulting in ongoing ovarian ablation (surgical menopause) [100]. Targeted radiation to the ovaries (ovarian irradiation) has been used as a form of ovarian ablation since the early 20th century and is also considered a form of OFS [101]

3.3 CDK4/6 Inhibitors

Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle regulation. Inhibition of these kinases can arrest the cell cycle and prevent tumor progression, particularly in HR+ breast cancer. CDK4/6 bind with cyclin D to phosphorylate the retinoblastoma (Rb) protein, freeing E2F transcription factors and permitting G1-to-S phase progression. Inhibition of CDK4/6 prevents Rb phosphorylation, halts cell cycle progression at the G1 checkpoint, and suppresses proliferation—especially effective in hormone receptor-positive breast cancer models. [102] [103].

3.4 PI3K/Akt/mTOR Pathway Inhibitors

The PI3K/Akt/mTOR signaling pathway is often dysregulated in breast cancer and contributes to tumor growth, survival, and resistance to therapy [105]. Inhibition of this pathway is promising therapeutic strategy.

Alpelisib: Alpelisib is a PI3K inhibitor that specifically targets the PIK3CA mutation, which is common in HR+ breast cancer [106]. Alpelisib is approved (in combination with fulvestrant) for HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer following progression on endocrine therapy [107]

Everolimus: Everolimus is an mTOR inhibitor approved for use in combination with exemestane for the treatment of HR+/HER2- metastatic breast cancer that has progressed after prior therapy with an AI [108] [109]. In the BOLERO-2 trial, everolimus plus exemestane significantly improved median progression-free survival compared to exemestane alone (7.8 months vs. 3.2 months; hazard ratio 0.45, $p < 0.0001$) [108]

Class	Example	Mechanism	use	toxicities
SERM	Tamoxifen	ER antagonist in breast	Premenopausal& postmenopausal prevention	Endometrial cancer,hot flashes
AI	Letrozole,Anastrozole,Exemestane	Blocks estrogen synthesis	postmenopausal	Bone loss ,arthralgia
SERD	Fulvestrant	ER degradation	Advanced/metastatic after SERM/AI	Hot flashes , injection site pain
OFS	Geserelin,Oophorectomy	Suppress ovarian estrogen	Premenopausal	Menopause symptoms
CDK4/6 inhibitors	Palbociclib,Ribociclib,Abemaciclib	Block cell-cycle progression	Advanced HR	Neutropenia,diarrhea
PI3K/mTOR inhibitors	Alpelisib,Everolimus	Block resistance pathways	Endocrine-resistant cases	Hyperglycemia,mucositis

PARP Inhibitors

Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in patients with breast cancer with BRCA1 or BRCA2 mutations, as these tumors are more susceptible to DNA damage via the principle of synthetic lethality. [110]. Olaparib and Talazoparib: Both of these PARP inhibitors have shown efficacy in BRCA-mutated, HER2-negative metastatic breast cancer, with olaparib improving progression-free survival in the OlympiAD trial (7.0 vs. 4.2 months; $p < 0.001$) [111] [112] —and talazoparib demonstrating significant benefit in the EMBRACA trial (PFS 7.0 vs. 4.2 months; ORR 62.6% vs. 27.2%) [35] [111].

4. Emerging and Future Therapies

As breast cancer therapy continues to evolve, several promising new approaches are being developed. These therapies aim to overcome existing challenges, such as drug resistance and limited efficacy in certain subtypes. [113]

4.1 Antibody-Drug Conjugates (ADCs)

ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, providing targeted delivery of chemotherapy to cancer cells [114]. ADCs deliver highly potent chemotherapy directly to cancer cells, minimizing systemic toxicity [115]. Approved examples include T-DM1, Trastuzumab Deruxtecan (T-DXd), and sacituzumab govitecan. [116] [117] They are expanding into HER2-low, HR-positive, and triple-negative subtypes. [118]. Trastuzumab Deruxtecan (T-DXd): A HER2-targeted ADC that delivers a highly potent chemotherapeutic agent, [119] T-DXd has shown impressive results in patients with HER2-low and HER2-positive breast cancers . [120]




FIG:4 This image explains the membrane of action of an Antibody-Drug Conjugate (ADC) used in targeted therapy for HER2-positive breast cancer. [121]

4.2 Immunotherapy

Immunotherapy has revolutionized cancer treatment by leveraging the immune system to target and eliminate cancer cells [122]. Immune checkpoint inhibitors shrink tumors in many patients - notably by blocking inhibitory signals such as PD-1/PD-L1 or CTLA-4, thereby unleashing anti-tumor T-cell responses [123]. They often provide lower toxicity and durable responses [124]. Immunotherapy has shown promise in the breast cancer, particularly TNBC. [122] Checkpoint Inhibitors: Drugs like pembrolizumab and atezolizumab, which target the PD-1/PD-L1 axis [125]. have demonstrated efficacy in certain TNBC patients, particularly those with high PD-L1 expression . [126]

Understanding the Side-effects of Checkpoints Inhibitors:

While immunotherapy is a breakthrough in cancer care, it can cause various adverse effects. Most commonly, patients may experience fatigue, nausea, coughing, decreased appetite or skin irritation. However, more severe complications can occur: Infusion-Related issues: During administration, some patients may experience an immediate allergic response. Symptoms like fever, difficulty breathing, facial flushing, or rashes should be reported to medical staff instantly. Immune-Mediated Responses: Because these drugs activate the immune system, the body may inadvertently attack its own healthy tissues. This can lead to serious inflammation in vital organs such as the lungs, kidneys, liver, or endocrine glands.

4.3 Nanotechnology and Drug Delivery Systems

Nanomedicine involves the use of nanoparticles for drug delivery [127], offering the potential to improve bioavailability and reduce side effects [128]. Nanoparticles can target tumors more precisely, allowing for the delivery of drugs directly to cancer cells while minimizing damage to surrounding healthy tissue. [129]

By utilizing specific nanocarriers, clinicians can improve the precision of drug delivery to malignant cells while increasing the duration that medications remain effective within the body. Modern non-delivery systems are capable of traversing complex physiological hurdles, such as the blood-brain barrier. These platforms offer several advantages, including high payload capacity, exceptional biocompatibility, structural adaptability, and highly accurate drug release mechanisms. These innovative delivery methods also help mitigate common challenges in conventional oncology, such as multi-drug resistance and p-glycoprotein mediated drug expulsion. Finally, the delivery process is optimized through the electrostatic attraction between positively charged nano-emulsions and the negatively charged surfaces of cancer cells. Nanocarriers can be engineered with an outer layer of antibodies to facilitate high precision delivery specifically to HER2-expressing cancer cells. This targeted nanomedicine approach has become a cornerstone in the treatment of HER2-related cancers .

4.4 Epigenetic Modifiers

Epigenetic alterations, such as DNA methylation and histone modification contribute to tumor progression and therapy resistance [130]. Agents targeting these epigenetic changes -such as HDAC inhibitors (e.g., entinostat, vorinostat) and DNMT inhibitors (e.g., decitabine, azacitidine)—are under investigation in both preclinical models and clinical trials for breast cancer, with particular focus on re-sensitizing endocrine-resistant and chemotherapy-resistant tumors to standard therapies [131] [132].

Challenges and Limitations

Despite the remarkable progress in targeted therapy, several challenges remain. These include:

Drug Resistance: Tumors may develop resistance to targeted therapies through mechanisms such as mutations, bypass signaling pathways, and clonal evolution. [133]. **High Cost:** Many of the newer targeted therapies are expensive, limiting their accessibility, particularly in low- and middle-income countries. [134]. **Need for Predictive Biomarkers:** Identifying biomarkers that predict response to specific therapies is critical for maximizing therapeutic efficacy and minimizing unnecessary Safety. [135]. **Toxicity and Safety:** Off-target effects of targeted therapies (eg. cardiotoxicity with HER2 inhibitors, hematological toxicity with CDK4/6 inhibitors). [136]. **Limited CNS Penetration :** Many targeted agents (HER2 therapies, CDK4/6 inhibitors) have poor blood-brain barrier penetration [137]. Brain metastases continue to pose a therapeutic challenge due to dismal prognosis, distinct biological resistance mechanisms, and significant limitations in effective drug delivery arising from the blood–brain and blood–tumor barriers as well as abnormal tumor perfusion and interstitial pressure [138]

6. FUTURE DIRECTIONS

The future of targeted therapy for breast cancer lies in personalized treatment approaches that integrate molecular profiling, advanced drug delivery systems, and combination therapies.

Personalized Medicine: The continued development of multi-omics approaches (genomics, proteomics, and metabolomics) will enable clinicians to select the most effective treatments based on individual tumor characteristics. [139]. **Therapies:** Combining targeted therapies with immunotherapy, chemotherapy, and other modalities may improve efficacy and overcome resistance [140]. **Gene Editing:** Technologies such as CRISPR hold promise for directly targeting genetic mutations in cancer cells, offering the potential for novel therapeutic interventions. [141]. **Novel Therapeutic Agents;** Biospecific antibodies-Targeted multiple antigens simultaneously. [142]. **Next generation ADCs:** Improved tumor selectively and payload delivery. [143]. **Targeting tumor microenvironment:** Angiogenesis inhibitors, immunomodulators. [144]

7. CONCLUSION

Targeted therapy has revolutionized breast cancer treatment, providing patients with more personalized and effective treatment options. Although significant progress has been made, challenges such as drug resistance, cost, and limited predictive biomarkers remain. Continued research into novel therapies, combination strategies, and personalized medicine will be key to improving outcomes for patients with breast cancer.

REFERENCES

1. ASung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209-249. doi:10.3322/caac.21660 <https://doi.org/10.3322/caac.21660>
2. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. *Nat Rev Dis Primers*. 2019;5(1):66. doi:10.1038/s41572-019-0111-2. <https://doi.org/10.1038/s41572-019-0111-2>
3. Waks AG, Winer EP. Breast cancer treatment: A review. *JAMA*. 2019;321(3):288-300. doi:10.1001/jama.2018.19323. <https://doi.org/10.1001/jama.2018.19323>
4. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. *Lancet*. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3. [https://doi.org/10.1016/S0140-6736\(20\)32381-3](https://doi.org/10.1016/S0140-6736(20)32381-3)
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747-752. doi:10.1038/35021093. <https://doi.org/10.1038/35021093>
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A*. 2001;98(19):10869-10874. doi:10.1073/pnas.191367098. <https://doi.org/10.1073/pnas.191367098>
7. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. *Mol Oncol*. 2011;5(1):5-23. doi:10.1016/j.molonc.2010.11.003. <https://doi.org/10.1016/j.molonc.2010.11.003>
8. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol*. 2014;5(3):412-424. doi:10.5306/wjco.v5.i3.412. <https://doi.org/10.5306/wjco.v5.i3.412>
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101. <https://doi.org/10.1056/NEJM200103153441101>
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122. <https://doi.org/10.1056/NEJMoa052122>

11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med.* 2005;353(16):1659-1672. doi:10.1056/NEJMoa052306. <https://doi.org/10.1056/NEJMoa052306>
12. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med.* 2015;372(8):724-734. doi:10.1056/NEJMoa1413513. <https://doi.org/10.1056/NEJMoa1413513>
13. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med.* 2012;367(19):1783-1791. doi:10.1056/NEJMoa1209124. <https://doi.org/10.1056/NEJMoa1209124>
14. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med.* 2020;382(7):610-621. doi:10.1056/NEJMoa1914510. <https://doi.org/10.1056/NEJMoa1914510>
15. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med.* 2020;382(7):597-609. doi:10.1056/NEJMoa1914609. <https://doi.org/10.1056/NEJMoa1914609>
16. Geyer CE Jr, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med.* 2006;355(26):2733-2743. doi:10.1056/NEJMoa064320. <https://doi.org/10.1056/NEJMoa064320>
17. Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive metastatic breast cancer. *N Engl J Med.* 2022;386(12):1143-1154. doi:10.1056/NEJMoa2115022. <https://doi.org/10.1056/NEJMoa2115022>
18. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med.* 2022;387(1):9-20. doi:10.1056/NEJMoa2203690. <https://doi.org/10.1056/NEJMoa2203690>
19. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med.* 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303. <https://doi.org/10.1056/NEJMoa1607303>
20. Hortobagyi GN, Stemmer SM, Burris HA III, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive advanced breast cancer. *N Engl J Med.* 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709. <https://doi.org/10.1056/NEJMoa1609709>
21. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer. *J Clin Oncol.* 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585. <https://doi.org/10.1200/JCO.2017.73.7585>
22. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol.* 2017;35(32):3638-3646. doi:10.1200/JCO.2017.75.6155. <https://doi.org/10.1200/JCO.2017.75.6155>
23. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone receptor-positive, advanced breast cancer (MONALEESA-7). *N Engl J Med.* 2018;379(7):652-662. doi:10.1056/NEJMoa1807650. <https://doi.org/10.1056/NEJMoa1807650>
24. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. *N Engl J Med.* 2020;382(6):514-524. doi:10.1056/NEJMoa1911149. <https://doi.org/10.1056/NEJMoa1911149>
25. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med.* 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904. <https://doi.org/10.1056/NEJMoa1813904>
26. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. *N Engl J Med.* 2012;366(6):520-529. doi:10.1056/NEJMoa1109653. <https://doi.org/10.1056/NEJMoa1109653>
27. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med.* 2017;377(6):523-533. doi:10.1056/NEJMoa1706450. <https://doi.org/10.1056/NEJMoa1706450>
28. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med.* 2018;379(8):753-763. doi:10.1056/NEJMoa1802905. <https://doi.org/10.1056/NEJMoa1802905>
29. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med.* 2018;379(22):2108-2121. doi:10.1056/NEJMoa1809615. <https://doi.org/10.1056/NEJMoa1809615>
30. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med.* 2020;382(9):810-821. doi:10.1056/NEJMoa1910549. <https://doi.org/10.1056/NEJMoa1910549>
31. Bardia A, Hurvitz SA, Tolane SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med.* 2021;384(16):1529-1541. doi:10.1056/NEJMoa2028485. <https://doi.org/10.1056/NEJMoa2028485>
32. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP clinical practice guideline focused update. *J Clin Oncol.* 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738. <https://doi.org/10.1200/JCO.2018.77.8738>

33. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173. <https://doi.org/10.1093/annonc/mdz173>
34. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. *J Natl Compr Canc Netw.* 2024;22(5):331-339. <https://jnccn.org/view/journals/jnccn/22/5/article-p331.xml>
35. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: St. Gallen International Consensus Guidelines. *Ann Oncol.* 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023. <https://doi.org/10.1016/j.annonc.2021.06.023>
36. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann Oncol.* 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010. <https://doi.org/10.1016/j.annonc.2020.09.010>
37. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med.* 2011;62:233-247. doi:10.1146/annurev-med-070909-182917. <https://doi.org/10.1146/annurev-med-070909-182917>
38. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. *Nat Rev Cancer.* 2009;9(9):631-643. doi:10.1038/nrc2713. <https://doi.org/10.1038/nrc2713>
39. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future. *Lancet.* 2020;395(10226):817-827. doi:10.1016/S0140-6736(20)30165-3. [https://doi.org/10.1016/S0140-6736\(20\)30165-3](https://doi.org/10.1016/S0140-6736(20)30165-3)
40. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone receptor-positive advanced breast cancer. *N Engl J Med.* 2015;373(3):209-219. doi:10.1056/NEJMoa1505270. <https://doi.org/10.1056/NEJMoa1505270>
41. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone receptor-positive metastatic breast cancer (PALOMA-3). *Lancet Oncol.* 2016;17(4):425-439. doi:10.1016/S1470-2045(15)00613-0. [https://doi.org/10.1016/S1470-2045\(15\)00613-0](https://doi.org/10.1016/S1470-2045(15)00613-0)
42. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone (PALOMA-1/TRIO-18). *Lancet Oncol.* 2015;16(1):25-35. doi:10.1016/S1470-2045(14)71159-3. [https://doi.org/10.1016/S1470-2045\(14\)71159-3](https://doi.org/10.1016/S1470-2045(14)71159-3)
43. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for HR-positive, HER2-negative advanced breast cancer. *J Clin Oncol.* 2020;38(34):3987-3998. doi:10.1200/JCO.20.02225. <https://doi.org/10.1200/JCO.20.02225>
44. Turner NC, Neven P, Loibl S, André F. Advances in the treatment of advanced oestrogen receptor-positive breast cancer. *Lancet.* 2017;389(10087):2403-2414. doi:10.1016/S0140-6736(16)32389-9. [https://doi.org/10.1016/S0140-6736\(16\)32389-9](https://doi.org/10.1016/S0140-6736(16)32389-9)
45. Fedele P, Orlando L, Schiavone P, et al. Recent advances in the treatment of HER2-positive breast cancer. *Cancers (Basel).* 2022;14(11):2644. doi:10.3390/cancers14112644. <https://doi.org/10.3390/cancers14112644>
46. Loibl S, Gianni L. HER2-positive breast cancer. *Lancet.* 2017;389(10087):2415-2429. doi:10.1016/S0140-6736(16)32417-5. [https://doi.org/10.1016/S0140-6736\(16\)32417-5](https://doi.org/10.1016/S0140-6736(16)32417-5)
47. Tarantino P, Hamilton E, Tolane SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: Pathological and clinical landscape. *J Clin Oncol.* 2020;38(17):1951-1962. doi:10.1200/JCO.19.02488. <https://doi.org/10.1200/JCO.19.02488>
48. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med.* 2014;138(2):241-256. doi:10.5858/arpa.2013-0953-SA. <https://doi.org/10.5858/arpa.2013-0953-SA>
49. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Final overall survival analysis of the CLEOPATRA study. *Lancet Oncol.* 2020;21(4):519-530. doi:10.1016/S1470-2045(19)30863-0. [https://doi.org/10.1016/S1470-2045\(19\)30863-0](https://doi.org/10.1016/S1470-2045(19)30863-0)
50. Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, et al. Efficacy of margetuximab versus trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer (SOPHIA). *J Clin Oncol.* 2021;39(23):2659-2671. doi:10.1200/JCO.20.03441. <https://doi.org/10.1200/JCO.20.03441>
51. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer (NALA trial). *J Clin Oncol.* 2020;38(27):3138-3149. doi:10.1200/JCO.20.00147. <https://doi.org/10.1200/JCO.20.00147>
52. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. *Clin Cancer Res.* 2020;26(12):2699-2706. doi:10.1158/1078-0432.CCR-19-2918. <https://doi.org/10.1158/1078-0432.CCR-19-2918>
53. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315-337. doi:10.1038/nrd.2016.268. <https://doi.org/10.1038/nrd.2016.268>
54. Lambert JM, Morris CQ. Antibody-drug conjugates for personalized treatment of solid tumors. *Adv Ther.* 2017;34(5):1015-1035. doi:10.1007/s12325-017-0528-6. <https://doi.org/10.1007/s12325-017-0528-6>
55. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin Cancer Res.* 2007;13(15):4429-4434. doi:10.1158/1078-0432.CCR-06-3045. <https://doi.org/10.1158/1078-0432.CCR-06-3045>
56. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med.* 2010;363(20):1938-1948. doi:10.1056/NEJMra1001389. <https://doi.org/10.1056/NEJMra1001389>

57. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple-negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res.* 2007;13(8):2329-2334. doi:10.1158/1078-0432.CCR-06-1109. <https://doi.org/10.1158/1078-0432.CCR-06-1109>
58. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011;121(7):2750-2767. doi:10.1172/JCI45014. <https://doi.org/10.1172/JCI45014>
59. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol.* 2016;13(11):674-690. doi:10.1038/nrclinonc.2016.66. <https://doi.org/10.1038/nrclinonc.2016.66>
60. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer: The road to targeted therapy. *Lancet.* 2017;389(10087):2430-2442. doi:10.1016/S0140-6736(16)32454-0. [https://doi.org/10.1016/S0140-6736\(16\)32454-0](https://doi.org/10.1016/S0140-6736(16)32454-0)
61. Emens LA. Breast cancer immunotherapy: Facts and hopes. *Clin Cancer Res.* 2018;24(3):511-520. doi:10.1158/1078-0432.CCR-16-3001. <https://doi.org/10.1158/1078-0432.CCR-16-3001>
62. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med.* 2022;386(6):556-567. doi:10.1056/NEJMoa2112651. <https://doi.org/10.1056/NEJMoa2112651>
63. Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol.* 2019;30(4):558-566. doi:10.1093/annonc/mdz012. <https://doi.org/10.1093/annonc/mdz012>
64. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med.* 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215. <https://doi.org/10.1056/NEJMoa2105215>
65. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA-mutated advanced breast cancer: Final overall survival results from EMBRACA. *Ann Oncol.* 2020;31(11):1526-1535. doi:10.1016/j.annonc.2020.08.2098. <https://doi.org/10.1016/j.annonc.2020.08.2098>
66. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up of adjuvant paclitaxel and trastuzumab trial for node-negative HER2-positive breast cancer. *J Clin Oncol.* 2019;37(22):1868-1875. doi:10.1200/JCO.19.00066. <https://doi.org/10.1200/JCO.19.00066>
67. Rugo HS, Bardia A, Tolaney SM, Arteaga CL, Cortés J, Sohn J, et al. KEYNOTE-355: Pembrolizumab plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. *J Clin Oncol.* 2022;40(16):1738-1748. doi:10.1200/JCO.21.02057. <https://doi.org/10.1200/JCO.21.02057>
68. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer (GeparNuevo). *Ann Oncol.* 2019;30(8):1279-1288. doi:10.1093/annonc/mdz158. <https://doi.org/10.1093/annonc/mdz158>
69. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M, et al. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *Arch Pathol Lab Med.* 2024;148(2):136-184. doi:10.5858/arpa.2023-0215-SA. <https://doi.org/10.5858/arpa.2023-0215-SA>
70. Harbeck N, Gnant M. Breast cancer. *Lancet.* 2017;389(10074):1134-1150. doi:10.1016/S0140-6736(16)31891-8. [https://doi.org/10.1016/S0140-6736\(16\)31891-8](https://doi.org/10.1016/S0140-6736(16)31891-8)
71. Polyak K. Heterogeneity in breast cancer. *J Clin Invest.* 2011;121(10):3786-3788. doi:10.1172/JCI60534. <https://doi.org/10.1172/JCI60534>
72. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. *Nature.* 2013;501(7467):355-364. doi:10.1038/nature12627. <https://doi.org/10.1038/nature12627>
73. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol.* 2018;15(2):81-94. doi:10.1038/nrclinonc.2017.166. <https://doi.org/10.1038/nrclinonc.2017.166>
74. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. *Nat Rev Cancer.* 2013;13(10):714-726. doi:10.1038/nrc3599. <https://doi.org/10.1038/nrc3599>
75. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013. <https://doi.org/10.1016/j.cell.2011.02.013>
76. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. *Nat Rev Cancer.* 2009;9(7):463-475. doi:10.1038/nrc2656. <https://doi.org/10.1038/nrc2656>
77. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315-337. doi:10.1038/nrd.2016.268. <https://doi.org/10.1038/nrd.2016.268>
78. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. *Nat Rev Cancer.* 2017;17(1):20-37. doi:10.1038/nrc.2016.108. <https://doi.org/10.1038/nrc.2016.108>
79. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol.* 2007;2(12):751-760. doi:10.1038/nnano.2007.387. <https://doi.org/10.1038/nnano.2007.387>
80. Fraguas-Sánchez AI, Lozza I, Torres-Suárez AI. Actively targeted nanomedicines in breast cancer: From preclinical investigation to clinical practice. *Cancers (Basel).* 2022;14(5):1198. doi:10.3390/cancers14051198. <https://doi.org/10.3390/cancers14051198>

81. Sitia L, Sevieri M, Signati L, Bonizzi A, Chiesa E, Mazzucchelli S, et al. HER2-targeted nanoparticles for breast cancer diagnosis and treatment. *Cancers (Basel)*. 2022;14(10):2424. doi:10.3390/cancers14102424. <https://doi.org/10.3390/cancers14102424>
82. Omidi Y, Mobasher M, Castejon AMC, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. *J Drug Target*. 2022;30(7):687-708. doi:10.1080/1061186X.2022.2055045. <https://doi.org/10.1080/1061186X.2022.2055045>
83. Jones PA, Baylin SB. The epigenomics of cancer. *Cell*. 2007;128(4):683-692. doi:10.1016/j.cell.2007.01.029. <https://doi.org/10.1016/j.cell.2007.01.029>
84. Baylin SB, Jones PA. Epigenetic determinants of cancer. *Cold Spring Harb Perspect Biol*. 2016;8(9):a019505. doi:10.1101/cshperspect.a019505. <https://doi.org/10.1101/cshperspect.a019505>
85. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. *Carcinogenesis*. 2010;31(1):27-36. doi:10.1093/carcin/bgp220. <https://doi.org/10.1093/carcin/bgp220>
86. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: Prospects and challenges. *J Clin Oncol*. 2013;31(15):1874-1884. doi:10.1200/JCO.2012.45.2263. <https://doi.org/10.1200/JCO.2012.45.2263>
87. Garraway LA, Verweij J, Ballman KV. Precision oncology: An overview. *J Clin Oncol*. 2013;31(15):1803-1805. doi:10.1200/JCO.2013.49.4799. <https://doi.org/10.1200/JCO.2013.49.4799>
88. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096. doi:10.1126/science.1258096. <https://doi.org/10.1126/science.1258096>
89. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. *Science*. 2017;355(6330):1152-1158. doi:10.1126/science.aam7344. <https://doi.org/10.1126/science.aam7344>
90. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*. 2005;434(7035):917-921. doi:10.1038/nature03445. <https://doi.org/10.1038/nature03445>
91. Emens LA. Breast cancer immunotherapy: Facts and hopes. *Clin Cancer Res*. 2018;24(3):511-520. doi:10.1158/1078-0432.CCR-16-3001. <https://doi.org/10.1158/1078-0432.CCR-16-3001>
92. Harbeck N, Gnant M. Breast cancer. *Lancet*. 2017;389(10074):1134-1150. doi:10.1016/S0140-6736(16)31891-8. [https://doi.org/10.1016/S0140-6736\(16\)31891-8](https://doi.org/10.1016/S0140-6736(16)31891-8)
93. Tarantino P, Corti C, Schmid P, Cortés J, Mittendorf EA, Rugo HS, et al. Advances in immunotherapy for breast cancer. *Nat Rev Clin Oncol*. 2024;21(2):118-137. doi:10.1038/s41571-023-00834-2. <https://doi.org/10.1038/s41571-023-00834-2>
94. Curigliano G, Tarantino P, et al. Open questions, current challenges, and future perspectives in targeting HER2-low breast cancer. *ESMO Open*. 2024;9:102989. doi:10.1016/j.esmoop.2024.102989. <https://doi.org/10.1016/j.esmoop.2024.102989>
95. Michelson I, Dacoregio MI, Vilbert M, et al. Antibody-drug conjugates in advanced/metastatic HER2-low-expressing breast cancer: A systematic review and meta-analysis. *Ther Adv Med Oncol*. 2024;16. doi:10.1177/17588359241297079. <https://doi.org/10.1177/17588359241297079>
96. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: Advances and future directions. *Nat Rev Drug Discov*. 2023;22(2):101-126. doi:10.1038/s41573-022-00579-0. <https://doi.org/10.1038/s41573-022-00579-0>
97. Chaudhari R, Patel V, Kumar A. Cutting-edge approaches for targeted drug delivery in breast cancer: Beyond conventional therapies. *Nanoscale Adv*. 2024;6:2270-2286. doi:10.1039/D4NA00086B. <https://doi.org/10.1039/D4NA00086B>
98. Patel S, et al. Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer. *J Pers Med*. 2024;14(7):723. doi:10.3390/jpm14070723. <https://doi.org/10.3390/jpm14070723>
99. Next-generation HER2-targeted antibody-drug conjugates in breast cancer. *Cancers (Basel)*. 2024;16(4):800. doi:10.3390/cancers16040800. <https://doi.org/10.3390/cancers16040800>
100. Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. *Breast*. 2024;78:103830. doi:10.1016/j.breast.2024.103830. <https://doi.org/10.1016/j.breast.2024.103830>
101. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—Latest advances and implications for cure. *Nat Rev Clin Oncol*. 2019;16(7):409-424. doi:10.1038/s41571-019-0187-3. <https://doi.org/10.1038/s41571-019-0187-3>
102. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. *Cancer Discov*. 2016;6(5):479-491. doi:10.1158/2159-8290.CD-15-1483. <https://doi.org/10.1158/2159-8290.CD-15-1483>
103. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—Implementation issues and future challenges. *Nat Rev Clin Oncol*. 2021;18(5):297-312. doi:10.1038/s41571-020-00457-x. <https://doi.org/10.1038/s41571-020-00457-x>
104. Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer. *Nature*. 2023;615:108-115. doi:10.1038/s41586-023-05795-5.
105. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;25(1):24-29. doi:10.1038/s41591-018-0316-z. <https://doi.org/10.1038/s41591-018-0316-z>
106. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7. <https://doi.org/10.1038/s41591-018-0300-7>

107. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med.* 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x. <https://doi.org/10.1038/s41591-018-0014-x>
108. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med.* 2013;19(11):1423-1437. doi:10.1038/nm.3394. <https://doi.org/10.1038/nm.3394>
109. Cortés J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: KEYNOTE-355 final results. *Ann Oncol.* 2024;35(1):68-79. doi:10.1016/j.annonc.2023.10.004 <https://doi.org/10.1016/j.annonc.2023.10.004>
110. Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant HER2-positive metastatic breast cancer (PANACEA). *Ann Oncol.* 2019;30(5):822-828. doi:10.1093/annonc/mdz017 <https://doi.org/10.1093/annonc/mdz017>
111. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in triple-negative breast cancer. *Lancet Oncol.* 2018;19(1):40-50. doi:10.1016/S1470-2045(17)30904-X [https://doi.org/10.1016/S1470-2045\(17\)30904-X](https://doi.org/10.1016/S1470-2045(17)30904-X)
112. Tolane SM, Wardley AM, Zambelli S, et al. Abemaciclib plus endocrine therapy in HR-positive early breast cancer (monarchE). *Ann Oncol.* 2020;31(12):1704-1712. doi:10.1016/j.annonc.2020.09.015 <https://doi.org/10.1016/j.annonc.2020.09.015>
113. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy: Updated safety analysis. *Breast Cancer Res Treat.* 2021;185(2):441-452. doi:10.1007/s10549-020-06021-x <https://doi.org/10.1007/s10549-020-06021-x>
114. Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 expression predicts resistance to CDK4/6 inhibition. *Cancer Cell.* 2019;35(6):947-959. doi:10.1016/j.ccell.2019.04.001 <https://doi.org/10.1016/j.ccell.2019.04.001>
115. Razavi P, Dickler MN, Shah PD, et al. Alterations in PTEN and ESR1 contribute to endocrine resistance in breast cancer. *Cancer Discov.* 2018;8(12):1504-1521. doi:10.1158/2159-8290.CD-18-0745 <https://doi.org/10.1158/2159-8290.CD-18-0745>
116. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. *Cancer Cell.* 2020;37(4):496-513. doi:10.1016/j.ccell.2020.03.009 <https://doi.org/10.1016/j.ccell.2020.03.009>
117. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. *Lancet Oncol.* 2012;13:e178-e185. doi:10.1016/S1470-2045(11)70335-7 [https://doi.org/10.1016/S1470-2045\(11\)70335-7](https://doi.org/10.1016/S1470-2045(11)70335-7)
118. Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors. *Cancer.* 2021;127(21):3897-3906. doi:10.1002/cncr.33739 <https://doi.org/10.1002/cncr.33739>
119. Modi S, Chandarlapaty S, Prat A, et al. Beyond HER2: New opportunities in HER2-low breast cancer. *Cancer Discov.* 2023;13(1):54-68. doi:10.1158/2159-8290.CD-22-0298 <https://doi.org/10.1158/2159-8290.CD-22-0298>
120. Tarantino P, Modi S, Tolane SM, et al. HER2-low breast cancer: Biology and evolving therapeutic landscape. *Nat Rev Clin Oncol.* 2024;21:57-73. doi:10.1038/s41571-023-00827-1 <https://doi.org/10.1038/s41571-023-00827-1>
121. Bardia A, Hurvitz SA. Targeting Trop-2 in metastatic breast cancer. *Clin Cancer Res.* 2023;29(8):1420-1428. doi:10.1158/1078-0432.CCR-22-2912 <https://doi.org/10.1158/1078-0432.CCR-22-2912>
122. Cortés J, Dent R, Cortes J, et al. Sacituzumab govitecan in hormone receptor-positive metastatic breast cancer. *N Engl J Med.* 2024;390:1397-1409. doi:10.1056/NEJMoa2301739 <https://doi.org/10.1056/NEJMoa2301739>
123. Rugo HS, Bardia A, Marmé F, et al. Datopotamab deruxtecan in advanced breast cancer. *N Engl J Med.* 2024;390:1325-1338. doi:10.1056/NEJMoa2310948 <https://doi.org/10.1056/NEJMoa2310948>
124. Modi S, Tsurutani J, Krop IE, et al. Trastuzumab deruxtecan: Mechanism and clinical development. *Clin Cancer Res.* 2021;27(15):4180-4190. doi:10.1158/1078-0432.CCR-20-4114 <https://doi.org/10.1158/1078-0432.CCR-20-4114>
125. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of sacituzumab govitecan in metastatic breast cancer. *J Clin Oncol.* 2021;39(22):2471-2481. doi:10.1200/JCO.20.03414 <https://doi.org/10.1200/JCO.20.03414>
126. Cortés J, O'Shaughnessy J, Blum JL, et al. Eribulin monotherapy versus physician's choice in metastatic breast cancer (EMBRACE): Final survival analysis. *Lancet Oncol.* 2012;13(6):593-603. doi:10.1016/S1470-2045(12)70122-4 [https://doi.org/10.1016/S1470-2045\(12\)70122-4](https://doi.org/10.1016/S1470-2045(12)70122-4)
127. Hanahan D. Hallmarks of cancer: New dimensions. *Cancer Discov.* 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059. <https://doi.org/10.1158/2159-8290.CD-21-1059>
128. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013. <https://doi.org/10.1016/j.cell.2011.02.013>
129. Polyak K, Metzger Filho O. SnapShot: Breast cancer. *Cell.* 2012;148(1-2):308.e1. doi:10.1016/j.cell.2011.12.033. <https://doi.org/10.1016/j.cell.2011.12.033>
130. Harbeck N, Penault-Llorca F, Cortes J, Gnani M, Houssami N, Poortmans P, et al. Breast cancer. *Nat Rev Dis Primers.* 2019;5(1):66. doi:10.1038/s41572-019-0112. <https://doi.org/10.1038/s41572-019-0112>
131. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol.* 2014;5(3):412-424. doi:10.5306/wjco.v5.i3.412. <https://doi.org/10.5306/wjco.v5.i3.412>

132. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: St. Gallen International Consensus Guidelines 2021. *Ann Oncol.* 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023. <https://doi.org/10.1016/j.annonc.2021.06.023>
133. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). *Ann Oncol.* 2018;29(8):1634-1657. doi:10.1093/annonc/mdy192. <https://doi.org/10.1093/annonc/mdy192>
134. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC5). *Ann Oncol.* 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010. <https://doi.org/10.1016/j.annonc.2020.09.010>
135. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. *J Natl Compr Canc Netw.* 2024;22(5):331-339. <https://jncn.org/view/journals/jncn/22/5/article-p331.xml>
136. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP guideline update. *J Clin Oncol.* 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738. <https://doi.org/10.1200/JCO.2018.77.8738>
137. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic: Implementation issues and future challenges. *Nat Rev Clin Oncol.* 2021;18(5):297-312. doi:10.1038/s41571-020-00457-x. <https://doi.org/10.1038/s41571-020-00457-x>
138. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease: Latest advances and implications for cure. *Nat Rev Clin Oncol.* 2019;16(7):409-424. doi:10.1038/s41571-019-0187-3. <https://doi.org/10.1038/s41571-019-0187-3>
139. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. *Cancer Discov.* 2016;6(5):479-491. doi:10.1158/2159-8290.CD-15-1483. <https://doi.org/10.1158/2159-8290.CD-15-1483>
140. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med.* 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x. <https://doi.org/10.1038/s41591-018-0014-x>
141. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med.* 2013;19(11):1423-1437. doi:10.1038/nm.3394. <https://doi.org/10.1038/nm.3394>
142. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. *Nat Med.* 2019;25(1):24-29. doi:10.1038/s41591-018-0316-z. <https://doi.org/10.1038/s41591-018-0316-z>
143. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7. <https://doi.org/10.1038/s41591-018-0300-7>
144. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science.* 2014;346(6213):1258096. doi:10.1126/science.1258096. <https://doi.org/10.1126/science.1258096>